pyrroles has been researched along with lovastatin in 181 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 25 (13.81) | 18.2507 |
| 2000's | 135 (74.59) | 29.6817 |
| 2010's | 21 (11.60) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bak Mueller, S; Bocan, TM; Dehart, P; Ferguson, E; Krause, BR; McNally, W; Newton, RS; Roth, BD; Sliskovic, DR; Uhlendorf, PD | 1 |
| Baader, E; Bartmann, W; Beck, G; Bergmann, A; Granzer, E; Jendralla, H; Kesseler, K; Krause, R; Schubert, W; von Kerekjarto, B | 1 |
| Ferguson, E; Krause, BR; Newton, RS; Roth, BD; Shaw, MK; Sliskovic, DR | 1 |
| Hoefle, ML; Newton, RS; Ortwine, DF; Roth, BD; Sliskovic, DR; Stratton, CD; Wilson, MW | 1 |
| Auerbach, BJ; Bisgaier, CL; Krause, BR; Newton, RS | 1 |
| Draper, CD; Hutson, JL; Inglis, GG; Procopiou, PA; Ross, BC; Watson, NS | 1 |
| Abe, Y; Ballantyne, CM; Dunn, K; Gotto, AM; Hackman, A; Insull, W; Pownall, H; Smith, L | 1 |
| Krause, BR; Newton, RS | 1 |
| Firth, JC; Marais, AD; Mountney, J; Naoumova, RP; Rendell, NB; Taylor, GW; Thompson, GR | 1 |
| Bakker-Arkema, R; Black, D; Davidson, M; Fayyad, R; McKenney, J; Schrott, H; Stein, E | 1 |
| Best, J; Black, D; Bracs, P; d'Emden, M; Dart, A; Hamilton-Craig, I; Jerums, G; Nicholson, G; Sullivan, D; Tallis, G; West, M | 1 |
| Roberts, WC | 1 |
| Hunninghake, D; Jones, P; Kafonek, S; Laurora, I | 1 |
| Wehmeier, T; Ziajka, PE | 1 |
| Pincus, J | 1 |
| Bakker-Arkema, RG; Black, DM; Brown, AS; Campbell, CF; Guthrie, R; Henley, RW; Koren, M; McLain, R; Woo, W; Yellen, L | 1 |
| Ballantyne, CM; Jacobson, TA; Schein, JR; Williamson, A | 1 |
| D'Agostino, RB; Ellison, RC; Hartz, SC; Huse, DM; Kraemer, DF; Miller, JD; Russell, MW | 1 |
| Bakker-Arkema, RG; Black, DM; Davidson, MH; Henley, RW; Hunninghake, DB; Koren, MJ; McKenney, JM; McLain, RW; Schrott, HG; Smith, DG; Tresh, P; Weiss, SR | 1 |
| Assang, C; Baillie, TA; Lin, JH; Lu, P; Ma, B; Meng, Y; Prueksaritanont, T; Reider, PJ; Tang, C | 1 |
| Frane, AM; Gantner, SE; Joyce, DM; Kersten, ME; Murdock, AK; Murdock, DK; Murdock, RW; Olson, KJ | 1 |
| Cao, Z; Cooper, ME; Cox, AJ; Gilbert, RE; Jandeleit-Dahm, K; Kelly, DJ | 1 |
| Blanco-Colio, LM; Egido, J; Guijarro, C; Kasiske, BL; Keane, WF; Massy, ZA; O'Donnell, MP | 1 |
| Farnier, M | 1 |
| Elkin, RG; Yan, Z | 1 |
| Bakker-Arkema, RG; Black, DM; Nawrocki, JW | 1 |
| Chan, M; Giannetti, N; Hayashi, S; Hunt, SA; Kato, T; Kobayashi, T; Morimoto, S; Namii, Y; Tokoro, T; Yokoyama, I | 1 |
| Auch-Schwelk, W; Elsner, M; Mach, S; Schächinger, V; Walter, DH; Zeiher, AM | 1 |
| Arnaboldi, L; Bellosta, S; Bernini, F; Corsini, A; Ferri, N; Paoletti, R | 1 |
| Dansette, PM; Jaoen, M; Pons, C | 1 |
| Förstermann, U; Hausding, M; Kleinert, H; Rodriguez-Pascual, F; von Eichel-Streiber, C; Witteck, A | 1 |
| Cromwell, WC; Ziajka, PE | 1 |
| Dotani, MI; Elnicki, DM; Gibson, CM; Jain, AC | 1 |
| Kwak, B; Mach, F; Mulhaupt, F; Myit, S | 1 |
| Davidson, MH | 1 |
| Stein, EA | 2 |
| Black, DM | 1 |
| Aspichueta, P; Díaz, C; Hernández, G; Hernández, ML; Isusi, E; Liza, M; Martínez, MJ; Ochoa, B | 1 |
| Crouch, MA | 1 |
| Harangi, M; Paragh, G | 1 |
| Agrusta, M; Amodio, M; Corigliano, G; De Simone, G; Gaeta, I; Gentile, S; Guarino, G; Magliano, P; Oliviero, B; Salvatore, T; Sasso, CF; Torella, R; Turco, S | 1 |
| Rosenson, RS; Schaefer, EJ; Tangney, CC | 1 |
| Lupattelli, G; Palumbo, B; Sinzinger, H | 1 |
| Dimitroulakos, J; Minden, MD; Penn, LZ; Tan, MM; Wong, WW; Xia, Z | 1 |
| Casciano, CN; Clement, RP; Johnson, WW; Wang, E | 1 |
| Schwartz, JB | 1 |
| Hamakubo, T; Inoue, K; Kitahara, M; Kodama, T; Morikawa, S; Nakagawa, S; Saito, Y; Suganami, H; Umetani, M; Yamazaki, H | 1 |
| Susekov, AV | 1 |
| Bakker-Arkema, RG; Black, DM; Corella, D; Ordovas, JM; Pedro-Botet, J; Schaefer, EJ; Stein, EM | 1 |
| Andrews, TC; Ballantyne, CM; Hsia, JA; Kramer, JH | 1 |
| Lee, TH | 1 |
| Basson, CT; Delanty, N; Vaughan, CJ | 1 |
| Auer, J; Eber, B | 1 |
| Igel, M; Sudhop, T; von Bergmann, K | 1 |
| Griffin, BP; Lauer, MS; Novaro, GM; Pearce, GL; Sprecher, DL; Tiong, IY | 1 |
| Bazalo, GR | 1 |
| Gierens, H; März, W; Nauck, M; Scharnagl, H; Schinker, R; Wieland, H | 1 |
| Alexander, S; Bilodeau, T; Carlson, W; Clark, M; Johnstone, M; Karam, C; Kinlay, S; Lloyd-Jones, DM; Orav, J; Ridker, PM; Rifai, N; Rubenstein, J; Stone, PH; Timms, T | 1 |
| Bellosta, S; Corsini, A; Paoletti, R | 1 |
| Edvinsson, L; Stenman, E; Xu, CB | 1 |
| Asztalos, BF; Horvath, KV; McNamara, JR; Roheim, PS; Rubinstein, JJ; Schaefer, EJ | 1 |
| Bannykh, S; England, JD; Gray, NL; Haas, RH; Hathaway, S; Kimura, BJ; Phillips, PS; Vladutiu, GD | 1 |
| Chmielewski, M; Rutkowski, B; Zdrojewski, Z | 1 |
| Alber, HF; Ares, MP; Dichtl, W; Dulak, J; Frick, M; Nilsson, J; Pachinger, O; Schwarzacher, SP; Weidinger, F | 1 |
| Sinzinger, H | 1 |
| Bays, HE; Crouse, JR; Dujovne, CA; Hutcheson, AG; Kashyap, ML; McGovern, ME; White, TE | 1 |
| Bouzamondo, A; Corvol, JC; Hulot, JS; Lechat, P; Sanchez, P; Sirol, M | 1 |
| McBurney, CR; Smith, DG | 1 |
| Clark, LT | 1 |
| Aicher, A; Assmus, B; Dimmeler, S; Haendeler, J; Hofmann, WK; Rössig, L; Spyridopoulos, I; Urbich, C; Zeiher, AM | 1 |
| Oguogho, A; Sinzinger, H | 1 |
| Brandle, M; Davidson, MB; Herman, WH; Lorber, B; Schriger, DL | 1 |
| Burger, F; Graber, P; Kwak, BR; Lüscher, TF; Mach, F; Matter, CM; Mulhaupt, F; Pelli, G; Veillard, NR | 1 |
| Bays, HE; McGovern, ME | 2 |
| Alber, H; Cisowski, J; Dichtl, W; Dulak, J; Frick, M; Józkowicz, A; Pachinger, O; Schwarzacher, SP; Weidinger, F; Zwick, R | 1 |
| Aicher, A; Badorff, C; Dimmeler, S; Fichtlscherer, S; Koyanagi, M; Rupp, S; Urbich, C; Zeiher, AM | 1 |
| Daly, JA; Ferrari, A; Gleason, JL; McNamara, JR; Rubenstein, JJ; Schaefer, EJ; Seman, LJ; Tayler, T | 1 |
| Borensztajn, J; Catron, DM; Haldar, K; Jones, BD; Lange, Y; Sylvester, MD | 1 |
| Johnson, R; Manfredi, F; Ormiston, T; Reus, VI; Wolkowitz, OM | 1 |
| Edwards, JE; Moore, RA | 1 |
| Mach, F | 1 |
| Horiuchi, S; Iida, KT; Matsuzaka, K; Nakagawa, Y; Nakakuki, M; Okazaki, H; Sakai, M; Sakamoto, Y; Shimano, H; Shu, M; Sone, H; Suzuki, H; Takahashi, A; Toyoshima, H; Yamada, N; Yokoo, T | 1 |
| Fang, CH; Li, JJ | 1 |
| Tellier, P | 1 |
| Clark, DS; Gerber, R; Ryan, JD | 1 |
| Mück, AO; Seeger, H; Wallwiener, D | 1 |
| Bernier, L; Chamberland, A; Davignon, J; Dubuc, G; Prat, A; Seidah, NG; Wassef, H | 1 |
| Eichelbaum, M; Fromm, MF; Kivistö, KT; Niemi, M; Pitkälä, K; Schaeffeler, E; Schwab, M; Strandberg, T; Tilvis, R | 1 |
| Dimmeler, S; Haendeler, J; Hoffmann, J; Zeiher, AM | 1 |
| Brummendorf, TH; Dimmeler, S; Haendeler, J; Oh, H; Schneider, MD; Spyridopoulos, I; Urbich, C; Zeiher, AM | 1 |
| Cartwright, MS; Donofrio, PD; Jeffery, DR; Nuss, GR | 1 |
| Deng, Y; DeRose, RA; Farber, SA; Ho, SY; Santana, E; Thorpe, JL | 1 |
| Campbell, SD; Chen, C; Lin, J; Mills, JB; Mireles, RJ; Smolarek, TA; Xu, JJ | 1 |
| Brousseau, ME; Kajinami, K; Lamon-Fava, S; Ordovas, JM; Schaefer, EJ | 1 |
| Adamson, P; Baker, D; Calder, V; Gegg, M; Greenwood, J; Hankey, D; Harry, R; Pryce, G; Zambarakji, H | 1 |
| Gibb, H; Scialli, AR | 1 |
| Abrahamowicz, M; Austin, PC; Eisenberg, MJ; Humphries, K; Pilote, L; Rahme, E; Tu, JV; Zhou, Z | 1 |
| Goez, P; Hagelgans, A; Hempel, U; Heyne, B; Jaross, W; Menschikowski, M; Neumeister, V; Siegert, G | 1 |
| Battisti, WP; Brady, WE; Denke, MA; McBride, PE; Palmisano, J; Pearson, TA | 1 |
| Brousseau, ME; Kajinami, K; Ordovas, JM; Schaefer, EJ | 1 |
| Bergman, M; Bessler, H; Djaldetti, M; Salman, H; Straussberg, R | 1 |
| Corpataux, JM; London, NJ; Naik, J; Porter, KE | 1 |
| Basha, SJ; Mullangi, R; Muzeeb, S; Pasha, MK; Shashikumar, D; Srinivas, NR | 1 |
| Blais, L; Bouchard, MH; Collin, J; Dragomir, A; Lalonde, L; Laurier, C; Perreault, S | 1 |
| Davidson, M | 1 |
| Jadhav, SB; Jain, GK | 1 |
| Crespo, MJ; Quidgley, JA | 1 |
| Baghestanian, M; Ghannadan, M; Hauswirth, AW; Krauth, MT; Majlesi, Y; Müller, MR; Samorapoompichit, P; Schernthaner, GH; Sonneck, K; Sperr, WR; Valent, P; Worda, C | 1 |
| Rosenson, RS | 1 |
| Foody, JM; Galusha, D; Havranek, EP; Krumholz, HM; Masoudi, FA; Radford, MJ; Rathore, SS | 1 |
| Castilla-Guerra, L; Espino-Montoro, A; Fernandez Moreno, Mdel C; Jimérnez, MD; López-Chozas, JM | 1 |
| Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M; Otsuka, Y | 1 |
| Ajith, TA; Soja, M | 1 |
| Burns, MP; Duff, K; Igbavboa, U; Wang, L; Wood, WG | 1 |
| Plans-Rubió, P | 1 |
| Lachaine, J; Merikle, EP; Rinfret, S; Tarride, JE | 1 |
| Adamovich, E; Allen, ZA; Butler, EG; Butler, WM; Galbreath, RW; Merrick, GS; Moyad, MA; Wallner, KE | 1 |
| Bestari, K; Brain, RA; Lissemore, LI; Reitsma, TS; Sibley, PK; Solomon, KR | 1 |
| Morais, MG; Pedrosa, R; Sena, A | 1 |
| Dellavalle, RP; Drake, AL; Freeman, SR; Graber, M; Heilig, LF; McNealy, K; Schilling, LM | 1 |
| Kitahara, K; Kohno, H; Okano, K; Saito, S; Sakai, T | 1 |
| Alsheikh-Ali, AA; Karas, RH | 1 |
| Galgóczy, L; Leiter, E; Lukács, G; Papp, T; Pócsi, I; Vágvölgyi, C | 1 |
| Choudhry, NK; Levin, R; Winkelmayer, WC | 1 |
| Batt, AM; Bertrand-Thiebault, C; Masson, C; Siest, G; Visvikis-Siest, S | 1 |
| Kazis, LE; Lee, A; Lee, TA; Li, NC; Wang, SW; Wolozin, B | 1 |
| Chen, C; Lin, J; Smolarek, T; Tremaine, L | 1 |
| Bergman, M; Bessler, H; Djaldetti, M; Salman, H | 2 |
| Coleman, CI; Dale, KM; Henyan, NN; Kluger, J; White, CM | 1 |
| George, J; Keren, G; Luboshits, G; Mausner-Fainberg, K; Maysel-Auslender, S; Mor, A; Rubinstein, A | 1 |
| Bhasin, B; Malhotra, S; Pandhi, P; Pattanaik, S; Shafiq, N; Singh, M; Venkateshan, SP | 1 |
| Hanson, ML; Kelly, SE; Richards, SM | 1 |
| Blasetto, J; Gandhi, S; Harley, CR; Heien, H; Nelson, SP; Sasane, R | 1 |
| Midgley, L; O'Regan, DJ; Porter, KE; Turner, NA | 1 |
| Behlouli, H; Eisenberg, MJ; Humphries, K; Pilote, L; Rinfret, S; Tu, JV | 1 |
| Gandhi, SK; Harley, CR; Heien, H; McDonough, K; Nelson, SP | 1 |
| Brenner, H; Hahmann, H; Hoffmann, MM; Rothenbacher, D; Vossen, CY; Wüsten, B | 1 |
| Avisar, I; Brook, JG; Wolfovitz, E | 1 |
| Dimitri, E; Landry, P; Légaré, N; Tessier, S | 1 |
| Fox, KM; Gandhi, SK; McKenney, JM; Ohsfeldt, RL | 1 |
| Xiao, H; Yang, CS | 1 |
| Ford, JS; Tayek, JA | 1 |
| Bérard, A; Blais, L; Dragomir, A; Lalonde, L; Perreault, S; White, M | 1 |
| Kumar, S; Liang, SL; Liu, H; Liu, W; Weyman, CM; Zhou, A | 1 |
| Avello L, M; Bravo D, M; Calvo M, C; Mennickent C, S | 1 |
| Freedland, SJ; Goldberg, KC; Hamilton, RJ; Platz, EA | 1 |
| Arora, P; Devereaux, PJ; Mills, EJ; Perri, D; Rachlis, B; Wu, P | 1 |
| Cheng, CC; Cheng, SM; Ho, LJ; Lai, JH; Liou, JT; Tsao, TP; Yang, SP | 1 |
| Glueck, CJ; Goldenberg, N; Khan, NA; Rawal, B; Wang, P; Yeramaneni, S | 1 |
| Abel, T; Fehér, J | 1 |
| Boring, D; Grubbs, CJ; Juliana, MM; Lubet, RA; Ruppert, JM; Steele, VE | 1 |
| Horna, A; Kulichová, B; Lopéz, SA; Nováková, L; Satínský, D; Solich, P; Solichová, D | 1 |
| Kromer, A; Moosmann, B | 1 |
| Jeon, TI; Osborne, TF; Seo, YK; Zhu, B | 1 |
| Hohenegger, M; Minichsdorfer, C | 1 |
| Boroumand, MA; Djalali, M; Eshragian, MR; Khatami, MR; Shojaei, MH; Siassi, F | 1 |
| Bil, J; Golab, J; Jakobisiak, M; Nowis, D; Zapala, L | 1 |
| Bate, A; Edwards, IR; Hägg, S; Strandell, J | 1 |
| Arranz Martínez, E; Gordillo López, FJ; Hermosa Hernán, JC; Ruiz García, A | 1 |
| Boutros, PC; Clendening, JW; Goard, CA; Martirosyan, A; Mather, RG; Penn, LZ; Sharom, FJ; Vinepal, B | 1 |
| Djalali, M; Eshraghian, M; Khatami, M; Shojaei, M; Siassi, F | 1 |
| D'Avolio, LW; Farwell, WR; Gaziano, JM; Lawler, EV; Scranton, RE | 1 |
| Barone, E; Butterfield, DA; Mancuso, C | 1 |
| Shi, J; Xue, Z | 1 |
| Boerner, JL; Bohin, N; Ge, Y; Irwin, ME; Mueller, KL | 1 |
| Tuğlu, MI; Vural, K | 1 |
| Dandri, M; Kah, J; Keller, AD; Montalbano, R; Ocker, M; Sass, G; Sirma, H; Tiegs, G; Volz, T; Wüstenberg, A | 1 |
| Alusi, G; Garcia, E; Giubellino, A; Grossman, AB; Korbonits, M; Nölting, S; Pacak, K | 1 |
| Dimbil, M; Golomb, BA; Hoffman, KB; Kraus, C | 1 |
| Bosch, J; García-Cardeña, G; García-Pagán, JC; Gracia-Sancho, J; Hide, D; Marrone, G; Rosado, E; Russo, L | 1 |
| Kitzmiller, JP; Phelps, MA; Sadee, W; Sullivan, DM; Wang, D | 1 |
| Abdoli, N; Azarmi, Y; Eghbal, MA; Heidari, R | 1 |
| Alderson, P; Lewis, SR; Nicholson, A; Sanders, RD; Smith, AF | 1 |
| Duleba, AJ; Ortega, I; Sokalska, A; Stanley, SD; Villanueva, JA | 1 |
| Horoshko, OM; Zamors'kyĭ, II; Zeleniuk, VH | 1 |
| Kitzmiller, JP; Luzum, JA; Phelps, MA; Wang, J | 1 |
| Carr, AJ; Cornell, HR; Hulley, PA; Kuzma-Kuzniarska, M; Moneke, MC | 1 |
32 review(s) available for pyrroles and lovastatin
| Article | Year |
|---|---|
Peripheral neuropathy and lipid-lowering therapy.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Naphthalenes; Niacin; Peripheral Nervous System Diseases; Pravastatin; Pyrroles; Simvastatin | 1998 |
Maximizing the cost-effectiveness of lipid-lowering therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Simvastatin | 1998 |
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; In Situ Hybridization; Kidney Diseases; Kidney Glomerulus; Lovastatin; Male; Nephrectomy; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Transforming Growth Factor beta | 1999 |
[The hyperlipidemias. Role of various statins].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 1999 |
Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Severity of Illness Index; Simvastatin; Treatment Outcome | 2000 |
Statin trials in progress: unanswered questions.
Topics: Atorvastatin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hypolipidemic Agents; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
New statins and new doses of older statins.
Topics: Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hypolipidemic Agents; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2001 |
Statins in children: what do we know and what do we need to do?
Topics: Atorvastatin; Bezafibrate; Child; Child Welfare; Cost-Benefit Analysis; Drug Approval; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
Effective use of statins to prevent coronary heart disease.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin | 2001 |
[The role of HDL in the prevention of cardiovascular events].
Topics: Anticholesteremic Agents; Arteriosclerosis; Aryldialkylphosphatase; Atorvastatin; Cholesterol, HDL; Esterases; Fatty Acids, Monounsaturated; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipid Peroxidation; Lovastatin; Phosphatidylcholine-Sterol O-Acyltransferase; Pyrroles; Simvastatin | 2001 |
Lipid-lowering medications: what the new guidelines and data mean to women.
Topics: Age Factors; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Male; Practice Guidelines as Topic; Pyrroles; Triglycerides | 2001 |
[Substantiation of increasing doses of statins in clinical practice].
Topics: Adult; Aged; Angiography; Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Colestipol; Coronary Disease; Dogs; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lovastatin; Male; Meta-Analysis as Topic; Middle Aged; Primates; Prospective Studies; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Time Factors | 2001 |
Statin therapy and stroke prevention.
Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Encephalitis; Endothelium, Vascular; Fibrinolytic Agents; Heptanoic Acids; Humans; Lovastatin; Nitric Oxide Synthase; Pyrroles; Stroke | 2001 |
A clinical focus on statins.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Down-Regulation; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Multicenter Studies as Topic; Myocardial Infarction; Practice Guidelines as Topic; Pravastatin; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Simvastatin | 2001 |
Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).
Topics: Atorvastatin; Drug Interactions; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
Managing dyslipidemia in the high-risk patient.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Niacin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2002 |
Pharmacological interactions of statins.
Topics: Atorvastatin; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Tolerance; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Muscular Diseases; Pyrroles; Rhabdomyolysis | 2002 |
Benefits and menaces related to the use of statins in patients after renal transplantation.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Transplantation; Lovastatin; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin | 2002 |
Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials.
Topics: Anticholesteremic Agents; Atorvastatin; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Risk Factors; Simvastatin; Stroke; Treatment Failure; Treatment Outcome | 2003 |
Treating dyslipidemia with statins: the risk-benefit profile.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Simvastatin; Stroke; Triglycerides; United States | 2003 |
Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2003 |
[Ezetimibe: from pharmacology to clinical trials].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Depression, Chemical; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Hypercholesterolemia; Intestinal Absorption; Liver; Lovastatin; Pravastatin; Pyrroles; Safety; Simvastatin; Treatment Outcome | 2003 |
Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis a
Topics: Animals; Atorvastatin; Chromatography, High Pressure Liquid; Fluorobenzenes; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pharmaceutical Preparations; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.
Topics: Atorvastatin; Comorbidity; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Failure, Chronic; Kidney Transplantation; Lovastatin; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Statins and osteoporosis: new role for old drugs.
Topics: Animals; Atorvastatin; Bone and Bones; Clinical Trials as Topic; Drug Delivery Systems; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Fractures, Bone; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Lovastatin; Osteogenesis; Osteoporosis; Pharmacokinetics; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Statins, fibrates, and melanoma risk: a systematic review and meta-analysis.
Topics: Atorvastatin; Bezafibrate; Clofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Incidence; Lovastatin; Melanoma; Odds Ratio; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Simvastatin; Skin Neoplasms; United States | 2006 |
Impact of statin dosing intensity on transaminase and creatine kinase.
Topics: Atorvastatin; Creatine Kinase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Function Tests; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Transaminases | 2007 |
A meta-analysis to evaluate the efficacy of statins in children with familial hypercholesterolemia.
Topics: Adolescent; Anticholesteremic Agents; Atorvastatin; Child; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides | 2007 |
Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Atorvastatin; Celecoxib; Colorectal Neoplasms; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Evidence-Based Medicine; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Meta-Analysis as Topic; Neoplasms; Pravastatin; Pyrazoles; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Sulfonamides; Sulindac | 2008 |
[Pleiotropic effects of statins].
Topics: Anticholesteremic Agents; Antioxidants; Atherosclerosis; Atorvastatin; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Oxidative Stress; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Confidence Intervals; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk | 2008 |
Perioperative statin therapy for improving outcomes during and after noncardiac vascular surgery.
Topics: Adult; Angioplasty; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Cause of Death; Cholestyramine Resin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Perioperative Care; Postoperative Complications; Pyrroles; Randomized Controlled Trials as Topic; Sitosterols; Vascular Surgical Procedures | 2013 |
25 trial(s) available for pyrroles and lovastatin
| Article | Year |
|---|---|
Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.
Topics: Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pyrroles; Treatment Outcome | 1997 |
A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Arthralgia; Atorvastatin; Cholesterol; Cholesterol, Dietary; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperhidrosis; Hyperlipidemias; Lovastatin; Male; Middle Aged; Patient Education as Topic; Pyrroles; Simvastatin; Triglycerides | 1997 |
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome | 1998 |
Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Colestipol; Combined Modality Therapy; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Indoles; Lovastatin; Male; Pyrroles; Simvastatin; Treatment Outcome | 1998 |
The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Female; Fluvastatin; Health Policy; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Pyrroles; Simvastatin; United States | 1998 |
Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease.
Topics: Adolescent; Adult; Atorvastatin; Cholesterol; Coronary Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Graft Rejection; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Lovastatin; Male; Middle Aged; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2000 |
Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin; Lovastatin; Male; Middle Aged; Placebos; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2000 |
Comparative study of HMG-CoA reductase inhibitors on fibrinogen.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Coronary Disease; Cross-Over Studies; Fatty Acids, Monounsaturated; Female; Fibrinogen; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 2001 |
Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner.
Topics: Anticholesteremic Agents; Apolipoproteins E; Atorvastatin; Double-Blind Method; Female; Genotype; Heptanoic Acids; Heterozygote; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Pyrroles; Sex Factors | 2001 |
Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Patient Education as Topic; Pravastatin; Pyrroles; Risk; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides; United States | 2001 |
Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angina Pectoris; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Heptanoic Acids; Humans; Hypolipidemic Agents; Lovastatin; Middle Aged; Myocardial Ischemia; Pyrroles; Time Factors; Treatment Outcome; Triglycerides | 2002 |
Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients.
Topics: Adult; Aged; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Maximum Tolerated Dose; Middle Aged; Pravastatin; Probability; Pyrroles; Reference Values; Severity of Illness Index; Simvastatin; Single-Blind Method; Treatment Outcome | 2002 |
Statin-associated myopathy with normal creatine kinase levels.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biopsy; Creatine Kinase; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Muscular Diseases; Pain; Pyrroles; Simvastatin | 2002 |
Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Time Factors | 2003 |
An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2003 |
Statin therapy in patients with coronary artery disease improves the impaired endothelial progenitor cell differentiation into cardiomyogenic cells.
Topics: Adult; Animals; Anticholesteremic Agents; Atorvastatin; Cell Differentiation; Cells, Cultured; Coronary Artery Disease; Endothelial Cells; Female; Heptanoic Acids; Humans; Lovastatin; Male; Myocytes, Cardiac; Pyrroles; Rats; Simvastatin | 2004 |
Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Fasting; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Indoles; Lipoproteins; Lovastatin; Male; Middle Aged; Postprandial Period; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2004 |
Hormonal changes with cholesterol reduction: a double-blind pilot study.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol; Double-Blind Method; Female; Heptanoic Acids; Hormones; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Male; Middle Aged; Pyrroles | 2004 |
Gender-specific effects of estrogen receptor alpha gene haplotype on high-density lipoprotein cholesterol response to atorvastatin: interaction with apolipoprotein AI gene polymorphism.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Double-Blind Method; Estrogen Receptor alpha; Female; Haplotypes; Heptanoic Acids; Humans; Lovastatin; Middle Aged; Pharmacogenetics; Placebos; Polymorphism, Genetic; Pyrroles; Sex Factors; Treatment Outcome | 2005 |
A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Nephelometry and Turbidimetry; Practice Guidelines as Topic; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin | 2005 |
A promoter polymorphism in cholesterol 7alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins E; Atorvastatin; Bile Acids and Salts; Cholesterol 7-alpha-Hydroxylase; Cholesterol, LDL; Double-Blind Method; Female; Genotype; Heptanoic Acids; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Placebos; Polymorphism, Genetic; Promoter Regions, Genetic; Pyrroles; Sex Factors; Treatment Outcome | 2005 |
Beneficial effect of statins in multiple sclerosis: is it dose-dependent?
Topics: Atorvastatin; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunologic Factors; Lovastatin; Multiple Sclerosis; Pyrroles; Simvastatin; Treatment Outcome | 2007 |
Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia.
Topics: Aged; Atorvastatin; Bezafibrate; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Treatment Outcome; Triglycerides | 2008 |
Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?
Topics: Atorvastatin; Cholesterol, LDL; Creatine Kinase; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rhabdomyolysis; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Effects of carnitine and coenzyme Q10 on lipid profile and serum levels of lipoprotein(a) in maintenance hemodialysis patients on statin therapy.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Carnitine; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoprotein(a); Lovastatin; Male; Middle Aged; Pyrroles; Renal Dialysis; Ubiquinone; Young Adult | 2011 |
124 other study(ies) available for pyrroles and lovastatin
| Article | Year |
|---|---|
Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Fatty Acids, Unsaturated; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Male; Pravastatin; Pyrroles; Rats; Rats, Inbred Strains; Sterols; Tetrazoles; Tissue Distribution | 1992 |
Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic (-heptanoic) acids.
Topics: Animals; Anticholesteremic Agents; Carcinoma, Hepatocellular; Chemical Phenomena; Chemistry; Cholesterol; Dogs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Neoplasms; Lovastatin; Male; Molecular Structure; Pyrroles; Rabbits; Rats; Structure-Activity Relationship; Tumor Cells, Cultured | 1990 |
Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase.
Topics: Animals; Atorvastatin; Carcinoma, Hepatocellular; Fatty Acids, Monounsaturated; Fatty Acids, Unsaturated; Fibroblasts; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver Neoplasms; Lovastatin; Male; Naphthalenes; Pravastatin; Pyrroles; Rats; Rats, Inbred Strains; Sterols; Tetrazoles; Tumor Cells, Cultured | 1990 |
Inhibitors of cholesterol biosynthesis. 1. trans-6-(2-pyrrol-1-ylethyl)-4-hydroxypyran-2-ones, a novel series of HMG-CoA reductase inhibitors. 1. Effects of structural modifications at the 2- and 5-positions of the pyrrole nucleus.
Topics: Animals; Chemical Phenomena; Chemistry; Chemistry, Physical; Cholesterol; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Liver; Lovastatin; Molecular Conformation; Molecular Structure; Pyrans; Pyrroles; Rats; Structure-Activity Relationship | 1990 |
Comparative effects of HMG-CoA reductase inhibitors on apo B production in the casein-fed rabbit: atorvastatin versus lovastatin.
Topics: Analysis of Variance; Animals; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Caseins; Cholesterol; Diet; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Iodine Radioisotopes; Lipoproteins, LDL; Lovastatin; Male; Pyrroles; Rabbits; Random Allocation | 1995 |
Inhibitors of cholesterol biosynthesis. 2. 3,5-Dihydroxy-7-(N-pyrrolyl)-6-heptenoates, a novel series of HMG-CoA reductase inhibitors.
Topics: Carcinoma, Hepatocellular; Cholesterol; Humans; Hydroxy Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Lovastatin; Molecular Structure; Pyrroles; Structure-Activity Relationship; Tumor Cells, Cultured | 1993 |
Levels of soluble cell adhesion molecules in patients with dyslipidemia.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cell Adhesion Molecules; Colestipol; Drug Therapy, Combination; E-Selectin; Endothelium, Vascular; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Intercellular Adhesion Molecule-1; Lovastatin; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin; Solubility; Vascular Cell Adhesion Molecule-1 | 1996 |
Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Guinea Pigs; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Liver; Lovastatin; Male; Pyrroles; Rabbits; Rats; Rats, Sprague-Dawley; Triglycerides | 1995 |
Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Enzyme Inhibitors; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lipoproteins, LDL; Lovastatin; Male; Mevalonic Acid; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 1996 |
The rule of 5 and the rule of 7 in lipid-lowering by statin drugs.
Topics: Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Lovastatin; Pravastatin; Pyrroles; Simvastatin | 1997 |
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 1998 |
Cost-effectiveness of statins.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Cost-Benefit Analysis; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Markov Chains; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 1998 |
Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.
Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Benzimidazoles; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Ketoconazole; Kinetics; Lovastatin; Mibefradil; Microsomes, Liver; Oxidoreductases, N-Demethylating; Pyridines; Pyrroles; Simvastatin; Tetrahydronaphthalenes | 1999 |
Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors; Treatment Outcome | 1999 |
Lipophilic statins induce apoptosis of human vascular smooth muscle cells.
Topics: Animals; Anticholesteremic Agents; Apoptosis; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscle, Smooth, Vascular; Pravastatin; Protein Prenylation; Pyrroles; Rats; Simvastatin | 1999 |
Relationship between inhibition of mevalonate biosynthesis and reduced fertility in laying hens.
Topics: Animals; Atorvastatin; Chickens; Enzyme Inhibitors; Female; Fertility; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insemination, Artificial; Lovastatin; Mevalonic Acid; Oviposition; Pyrroles; Simvastatin | 1999 |
Effect of statin therapy on restenosis after coronary stent implantation.
Topics: Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Coronary Angiography; Coronary Disease; Disease-Free Survival; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hyperplasia; Indoles; Lovastatin; Male; Middle Aged; Pyrroles; Recurrence; Retrospective Studies; Simvastatin; Stents; Time Factors; Tunica Intima | 2000 |
Pleiotropic effects of statins in atherosclerosis and diabetes.
Topics: Animals; Arteriosclerosis; Atorvastatin; Cell Division; Cell Movement; Cells, Cultured; Cholesterol; Cholesterol Esters; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Endocytosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins; Lovastatin; Macrophages; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Muscle, Smooth; Pyridines; Pyrroles; Simvastatin | 2000 |
HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins.
Topics: Animals; Atorvastatin; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Microsomes, Liver; Pravastatin; Pyridines; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Species Specificity | 2000 |
Inhibition of small G proteins of the rho family by statins or clostridium difficile toxin B enhances cytokine-mediated induction of NO synthase II.
Topics: 3T3 Cells; Animals; Atorvastatin; Bacterial Proteins; Bacterial Toxins; Cytokines; Drug Interactions; Enzyme Induction; Gene Expression Regulation, Enzymologic; GTP-Binding Proteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mevalonic Acid; Mice; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Polyisoprenyl Phosphates; Promoter Regions, Genetic; Pyrroles; rho GTP-Binding Proteins; Tumor Cells, Cultured | 2000 |
Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors.
Topics: Atorvastatin; Cholesterol, LDL; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Least-Squares Analysis; Linear Models; Lovastatin; Nonlinear Dynamics; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin; Tachyphylaxis; Time Factors | 2000 |
Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting.
Topics: Aged; Anticholesteremic Agents; Arrhythmias, Cardiac; Atorvastatin; Cause of Death; Coronary Artery Bypass; Coronary Disease; Female; Heart Failure; Heptanoic Acids; Humans; Hypercholesterolemia; Incidence; Lovastatin; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Preoperative Care; Pyrroles; Recurrence; Retrospective Studies; Risk Factors; Simvastatin; Stroke; Treatment Outcome | 2000 |
Statins as a newly recognized type of immunomodulator.
Topics: Adjuvants, Immunologic; Anticholesteremic Agents; Atorvastatin; Endothelium, Vascular; Genes, MHC Class II; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Lovastatin; Lymphocyte Activation; Macrophages; Monocytes; Nuclear Proteins; Pravastatin; Pyrroles; Saphenous Vein; T-Lymphocytes; Trans-Activators | 2000 |
Short- and long-term effects of atorvastatin, lovastatin and simvastatin on the cellular metabolism of cholesteryl esters and VLDL secretion in rat hepatocytes.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cells, Cultured; Cholesterol Esters; Female; Heptanoic Acids; Lipoproteins, VLDL; Liver; Lovastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin | 2000 |
Statin induced myopathy does not show up in MIBI scintigraphy.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Breast Neoplasms; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lovastatin; Male; Middle Aged; Muscle, Skeletal; Muscular Diseases; Pain; Pravastatin; Pyridines; Pyrroles; Radionuclide Imaging; Radiopharmaceuticals; Simvastatin; Technetium Tc 99m Sestamibi | 2001 |
Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin.
Topics: Acute Disease; Apoptosis; Atorvastatin; Cell Division; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Leukemia, Myeloid; Lovastatin; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyridines; Pyrroles; Sensitivity and Specificity; Tumor Cells, Cultured | 2001 |
HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein.
Topics: 3T3 Cells; Adenosine Triphosphate; Animals; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Pravastatin; Pyrroles; Simvastatin | 2001 |
Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells.
Topics: Atorvastatin; Cell Line; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lovastatin; Pravastatin; Pyrroles; Quinolines; Receptors, LDL; RNA, Messenger; Simvastatin | 2000 |
By the way, doctor... My brother takes Mevacor and has been told to take the drug at bedtime. But when I started on Lipitor, my doctor said to take the medication at any time of the day. Why the difference?
Topics: Anticholesteremic Agents; Atorvastatin; Drug Administration Schedule; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Pyrroles | 2001 |
Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis.
Topics: Aged; Aortic Valve Stenosis; Atorvastatin; Calcinosis; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Echocardiography; Electrocardiography; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Multivariate Analysis; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides; Vascular Patency | 2001 |
Managed care trends in statin usage.
Topics: Anticholesteremic Agents; Atorvastatin; Databases, Factual; Drug Costs; Drug Utilization Review; Fatty Acids, Monounsaturated; Fluvastatin; Health Care Sector; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Managed Care Programs; Pravastatin; Pyridines; Pyrroles; Simvastatin; United States | 2001 |
Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells.
Topics: Anticholesteremic Agents; Atorvastatin; CCAAT-Enhancer-Binding Proteins; Cholesterol; DNA-Binding Proteins; fas Receptor; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lovastatin; Pyrroles; Receptors, LDL; Simvastatin; Sterol Regulatory Element Binding Protein 1; Transcription Factors; Triglycerides; Tumor Cells, Cultured | 2001 |
Reduction of bFGF-induced smooth muscle cell proliferation and endothelin receptor mRNA expression by mevastatin and atorvastatin.
Topics: Animals; Anticholesteremic Agents; Aorta; Atorvastatin; Cell Division; Cerebral Arteries; Drug Interactions; Endothelin Receptor Antagonists; Fibroblast Growth Factor 2; Heptanoic Acids; Lovastatin; Male; Muscle, Smooth; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors | 2002 |
Summaries for patients. Muscle abnormalities in four patients taking statins to treat unfavorable cholesterol levels.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biopsy; Creatine Kinase; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Muscular Diseases; Pain; Pyrroles; Simvastatin | 2002 |
HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells.
Topics: Atorvastatin; Cell Line; Cell Survival; Down-Regulation; Endothelial Growth Factors; Endothelium, Vascular; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoxia-Inducible Factor 1, alpha Subunit; I-kappa B Proteins; Inflammation; Lovastatin; Muscle, Smooth, Vascular; NF-kappa B; NF-KappaB Inhibitor alpha; Plasminogen Activator Inhibitor 1; Protein Binding; Proto-Oncogene Proteins c-jun; Pyrroles; RNA, Messenger; Simvastatin; Transcription Factor AP-1; Transcription Factors; Vascular Endothelial Growth Factor A | 2003 |
Statin-induced myositis migrans.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Myositis; Pravastatin; Pyrroles; Simvastatin; Time Factors | 2002 |
HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes.
Topics: Atorvastatin; Cell Cycle Proteins; Cell Division; Cells, Cultured; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Endothelium, Vascular; Gene Expression Profiling; Gene Expression Regulation; Genes, cdc; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes, Mononuclear; Lovastatin; Oligonucleotide Array Sequence Analysis; Pyrroles; Signal Transduction; Stem Cells; Telomerase; Tumor Suppressor Proteins | 2003 |
Variable influence of statins on isoprostanes in hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Dinoprost; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Isoprostanes; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Smoking | 2003 |
Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Sensitivity and Specificity; Simvastatin; United States | 2003 |
Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells.
Topics: Animals; Arteriosclerosis; Atorvastatin; Blotting, Western; CD40 Antigens; Cells, Cultured; Depression, Chemical; Dose-Response Relationship, Drug; Endothelial Cells; Fibroblasts; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Interferon-gamma; Lovastatin; Macrophages; Mevalonic Acid; Mice; Muscle, Smooth, Vascular; Nitric Oxide Synthase; Pravastatin; Pyrroles; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Simvastatin; Transcription Factors | 2003 |
Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Combinations; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Niacin; Particle Size; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2003 |
Statins differentially regulate vascular endothelial growth factor synthesis in endothelial and vascular smooth muscle cells.
Topics: Atorvastatin; Cells, Cultured; Coronary Vessels; Dose-Response Relationship, Drug; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscle, Smooth, Vascular; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Simvastatin; Umbilical Veins; Vascular Endothelial Growth Factor A | 2003 |
Salmonella enterica serovar Typhimurium requires nonsterol precursors of the cholesterol biosynthetic pathway for intracellular proliferation.
Topics: Animals; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Lovastatin; Macrophages; Mice; Mice, Inbred BALB C; Pyrroles; Salmonella typhimurium | 2004 |
Toward a role for statins in immunomodulation.
Topics: Adjuvants, Immunologic; Animals; Atorvastatin; Autoimmune Diseases; Cytokines; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Genes, MHC Class II; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Indoles; Lovastatin; Mice; Pravastatin; Pyrroles; Simvastatin | 2002 |
Statins downregulate ATP-binding-cassette transporter A1 gene expression in macrophages.
Topics: Animals; Atorvastatin; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Biological Transport; Blotting, Northern; Cell Line; Cholesterol; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Luciferases; Macrophages; Mice; Oxygen; Promoter Regions, Genetic; Pyrroles; RNA, Messenger; Simvastatin; Swiss 3T3 Cells; Time Factors; Transcription, Genetic | 2004 |
C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
Topics: Acute-Phase Reaction; Aspirin; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Artery Disease; Heptanoic Acids; Humans; Incidence; Inflammation; Interleukin-6; Lovastatin; Pravastatin; Predictive Value of Tests; Pyrroles; Risk Factors; Simvastatin | 2004 |
Cell-based screen of HMG-CoA reductase inhibitors and expression regulators using LC-MS.
Topics: Atorvastatin; Biological Assay; Calibration; Cell Line; Chromatography, Liquid; Enzyme Induction; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Humans; Hydroxycholesterols; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mass Spectrometry; Mevalonic Acid; Pyrroles; Simvastatin | 2004 |
Class-specific pro-apoptotic effect of statins on human vascular endothelial cells.
Topics: Apoptosis; Atorvastatin; Cell Division; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Fas Ligand Protein; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Membrane Glycoproteins; Metabolic Clearance Rate; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Simvastatin; Umbilical Veins | 2004 |
Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia.
Topics: Alitretinoin; Animals; Atorvastatin; Base Sequence; Cell Line; Cholesterol; Consensus Sequence; DNA-Binding Proteins; Gene Expression Regulation; Hepatocytes; Heptanoic Acids; Homeostasis; Humans; Hydroxycholesterols; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver X Receptors; Lovastatin; Mevalonic Acid; Mice; Orphan Nuclear Receptors; Promoter Regions, Genetic; Proprotein Convertase 9; Proprotein Convertases; Pyridines; Pyrroles; Quinolines; Rats; Receptors, Cytoplasmic and Nuclear; Regulatory Sequences, Nucleic Acid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Alignment; Sequence Homology, Nucleic Acid; Serine Endopeptidases; Simvastatin; Sp1 Transcription Factor; Species Specificity; Sterol Regulatory Element Binding Protein 2; Transcription Factors; Tretinoin | 2004 |
Lipid-lowering response to statins is affected by CYP3A5 polymorphism.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Genotype; Heptanoic Acids; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Polymorphism, Genetic; Pyrroles; Simvastatin | 2004 |
Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins.
Topics: Amino Acid Substitution; Antioxidants; Atorvastatin; Cells, Cultured; Cysteine; Endothelial Cells; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mutagenesis, Site-Directed; Nitric Oxide; Oxidation-Reduction; Oxidative Stress; Protein Processing, Post-Translational; Pyrroles; Reactive Oxygen Species; Recombinant Fusion Proteins; S-Nitrosothiols; Simvastatin; Thioredoxins; Transfection; Umbilical Veins | 2004 |
Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells.
Topics: Adenoviridae; Amino Acid Sequence; Atorvastatin; Cell Movement; Cells, Cultured; Cellular Senescence; Checkpoint Kinase 2; Endothelial Cells; Endothelium, Vascular; Enzyme Induction; Flow Cytometry; Genetic Vectors; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Situ Hybridization, Fluorescence; Interleukin-4; Lovastatin; Macrophage Colony-Stimulating Factor; Molecular Sequence Data; Protein Serine-Threonine Kinases; Pyrroles; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Telomere; Telomeric Repeat Binding Protein 2; Vascular Endothelial Growth Factor A | 2004 |
Statin-associated exacerbation of myasthenia gravis.
Topics: Atorvastatin; Cytokines; Dysarthria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Lovastatin; Male; Middle Aged; Mitochondria; Models, Neurological; Muscular Diseases; Myasthenia Gravis; Neural Conduction; Pravastatin; Pyridostigmine Bromide; Pyrroles; Simvastatin; Th2 Cells; Ubiquinone | 2004 |
Lipid metabolism in zebrafish.
Topics: 4-Chloro-7-nitrobenzofurazan; Alkyl and Aryl Transferases; Animals; Annexin A2; Atorvastatin; Azetidines; Boron Compounds; Caveolin 1; Caveolins; Cell Movement; Cholesterol; Diterpenes; DNA; Embryo, Nonmammalian; Ethylnitrosourea; Ezetimibe; Farnesol; Farnesyltranstransferase; Geranyltranstransferase; Germ Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipids; Lovastatin; Mevalonic Acid; Microscopy, Fluorescence; Mutagenesis, Site-Directed; Mutation; Phosphatidylethanolamines; Protein Binding; Protein Prenylation; Pyrroles; Simvastatin; Zebrafish | 2004 |
Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1.
Topics: Adenosine Triphosphate; Animals; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Dogs; Estradiol; Fluoresceins; Heptanoic Acids; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Permeability; Pyrroles; Simvastatin; Structure-Activity Relationship | 2005 |
Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction.
Topics: Administration, Oral; Animals; Atorvastatin; Autoimmune Diseases; Cell Line; Cell Migration Inhibition; Cell Proliferation; Cytokines; Female; Growth Inhibitors; Heptanoic Acids; Humans; Immunosuppressive Agents; Injections, Intraperitoneal; Lovastatin; Male; Mice; Mice, Inbred C57BL; Pyrroles; Rats; Rats, Inbred Lew; Retinitis; Th2 Cells; Uveitis | 2005 |
Statin drugs and congenital anomalies.
Topics: Abnormalities, Drug-Induced; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infant, Newborn; Lovastatin; Pregnancy; Pregnancy Outcome; Pyrroles; Simvastatin | 2005 |
Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.
Topics: Aged; Atorvastatin; Cohort Studies; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Mortality; Myocardial Infarction; Patient Compliance; Pravastatin; Proportional Hazards Models; Pyrroles; Retrospective Studies; Secondary Prevention; Simvastatin; Survival Analysis | 2005 |
Statins potentiate the IFN-gamma-induced upregulation of group IIA phospholipase A2 in human aortic smooth muscle cells and HepG2 hepatoma cells.
Topics: Amides; Aorta; Atorvastatin; Bacterial Proteins; Bacterial Toxins; Butadienes; Carcinoma, Hepatocellular; CCAAT-Enhancer-Binding Proteins; Cell Line, Tumor; Drug Synergism; Flavonoids; Group II Phospholipases A2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Janus Kinase 2; Lovastatin; Myocytes, Smooth Muscle; NF-kappa B; Nitriles; Phospholipases A; Phospholipases A2; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyridines; Pyrroles; RNA Stability; Up-Regulation | 2005 |
In vitro effect of statins on cytokine production and mitogen response of human peripheral blood mononuclear cells.
Topics: Atorvastatin; Cell Proliferation; Cytokines; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Leukocytes, Mononuclear; Lovastatin; Mitogens; Pravastatin; Pyrroles; Simvastatin | 2005 |
The effect of six different statins on the proliferation, migration, and invasion of human smooth muscle cells.
Topics: Atorvastatin; Cell Division; Cell Movement; Chemotaxis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Myocytes, Smooth Muscle; Pravastatin; Pyridines; Pyrroles; Saphenous Vein; Simvastatin | 2005 |
Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease.
Topics: Atorvastatin; Cardiovascular Diseases; Drug Prescriptions; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Patient Compliance; Pyrroles; Regression Analysis; Time Factors | 2005 |
Time as a variable with niacin extended-release/lovastatin vs. atorvastatin and simvastatin.
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Niacin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2005 |
Statins decrease serotonin-induced contractions in coronary arteries of swine in vitro.
Topics: Animals; Atorvastatin; Coronary Vessels; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Male; Pravastatin; Pyrroles; Serotonin; Simvastatin; Swine; Time Factors; Vasoconstriction | 2006 |
Effects of various statins on cytokine-dependent growth and IgE-dependent release of histamine in human mast cells.
Topics: Apoptosis; Atorvastatin; Cell Differentiation; Cell Division; Cell Proliferation; Cells, Cultured; Cytokines; Heptanoic Acids; Histamine Release; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin E; Lovastatin; Mast Cells; Probability; Pyridines; Pyrroles; Sensitivity and Specificity | 2006 |
Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Particle Size; Polymorphism, Genetic; Pravastatin; Pyrroles; Risk Factors; Simvastatin | 2006 |
Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: evidence for an age-statin interaction.
Topics: Age Factors; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Drug Prescriptions; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Myocardial Infarction; Odds Ratio; Pravastatin; Pyridines; Pyrroles; Retrospective Studies; Survival Rate; Treatment Outcome | 2006 |
Statins and stroke: current clinical practice.
Topics: Age Factors; Atorvastatin; Cholesterol; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Pyrroles; Secondary Prevention; Simvastatin; Stroke | 2006 |
Inhibitory effects of statins on human monocarboxylate transporter 4.
Topics: Animals; Atorvastatin; Basigin; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lactic Acid; LLC-PK1 Cells; Lovastatin; Monocarboxylic Acid Transporters; Muscle Proteins; Pyridines; Pyrroles; Simvastatin; Swine; Transfection | 2006 |
A comparative study on the antimutagenicity of atorvastatin and lovastatin against directly acting mutagens.
Topics: Anticarcinogenic Agents; Antimutagenic Agents; Atorvastatin; Carcinoma; Cell Line, Tumor; DNA Damage; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Lovastatin; Mutagenesis; Mutagenicity Tests; Mutagens; Mutation; Pyrroles; Salmonella; Salmonella typhimurium | 2006 |
Cholesterol distribution, not total levels, correlate with altered amyloid precursor protein processing in statin-treated mice.
Topics: Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Anticholesteremic Agents; Atorvastatin; Cell Membrane; Central Nervous System; Cholesterol; Ergosterol; Heptanoic Acids; Lovastatin; Male; Mice; Peptide Fragments; Pyrroles; Simvastatin; Synaptosomes | 2006 |
Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Meta-Analysis as Topic; Pravastatin; Pyrroles; Risk Factors; Simvastatin; Spain | 2006 |
Persistence and adherence to cholesterol lowering agents: evidence from Régie de l'Assurance Maladie du Québec data.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Databases, Factual; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Patient Compliance; Pravastatin; Pyrroles; Quebec; Registries; Retrospective Studies; Simvastatin | 2006 |
Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer.
Topics: Aged; Atorvastatin; Biopsy; Brachytherapy; Cause of Death; Chemotherapy, Adjuvant; Chi-Square Distribution; Disease-Free Survival; Fatty Acids, Monounsaturated; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Neoplasm Staging; Pravastatin; Proportional Hazards Models; Prostatic Neoplasms; Pyrroles; Retrospective Studies; Simvastatin; Survival Analysis | 2006 |
Herbicidal effects of statin pharmaceuticals in Lemna gibba.
Topics: Atorvastatin; Chromatography, High Pressure Liquid; Heptanoic Acids; Herbicides; Hydroxymethylglutaryl CoA Reductases; Lovastatin; Mevalonic Acid; Models, Chemical; Pharmaceutical Preparations; Plants; Plastoquinone; Pyrroles; Risk Assessment; Sitosterols; Sterols; Ubiquinone; Ultraviolet Rays | 2006 |
Treatment of experimental autoimmune uveoretinitis with atorvastatin and lovastatin.
Topics: Administration, Oral; Animals; Arrestin; Atorvastatin; Autoimmune Diseases; Cattle; Cell Proliferation; Cytokines; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypersensitivity, Delayed; Immunohistochemistry; Injections, Intraperitoneal; Lovastatin; Lymph Nodes; Macrophages; Models, Animal; Pyrroles; Rats; Rats, Inbred Lew; Retina; Retinitis; T-Lymphocytes; Uvea; Uveitis | 2007 |
Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
Topics: Adverse Drug Reaction Reporting Systems; Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Prescriptions; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver Diseases; Lovastatin; Niacin; Pravastatin; Prevalence; Pyrroles; Retrospective Studies; Rhabdomyolysis; Risk Factors; Simvastatin; United States; United States Food and Drug Administration | 2007 |
Interactions between statins and Penicillium chrysogenum antifungal protein (PAF) to inhibit the germination of sporangiospores of different sensitive Zygomycetes.
Topics: Antifungal Agents; Atorvastatin; Dose-Response Relationship, Drug; Drug Synergism; Fluorobenzenes; Fungi; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Microbial Sensitivity Tests; Penicillium chrysogenum; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Spores, Fungal; Sulfonamides | 2007 |
Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice.
Topics: Aged; Atorvastatin; Chi-Square Distribution; Coronary Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Pravastatin; Proportional Hazards Models; Pyrroles; Recurrence; Retrospective Studies; Simvastatin; Treatment Outcome | 2007 |
Effect of HMGCoA reductase inhibitors on cytochrome P450 expression in endothelial cell line.
Topics: Analysis of Variance; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Blotting, Western; Cell Line; Cell Proliferation; Cell Survival; Constitutive Androstane Receptor; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme System; Endothelial Cells; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pregnane X Receptor; Pyrroles; Receptors, Cytoplasmic and Nuclear; Receptors, Glucocorticoid; Receptors, Steroid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Saphenous Vein; Transcription Factors; Up-Regulation | 2007 |
Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease.
Topics: Age Factors; Aged; Aged, 80 and over; Atorvastatin; Databases as Topic; Dementia; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Male; Parkinson Disease; Proportional Hazards Models; Pyrroles; Simvastatin; United States; Veterans | 2007 |
P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Brain; Heptanoic Acids; Lactones; Liver; Lovastatin; Male; Mice; Mice, Inbred Strains; Mice, Knockout; Pravastatin; Pyrroles; Simvastatin | 2007 |
On the factors modulating the effect of statins on malignant cell proliferation.
Topics: Annexin A5; Atorvastatin; Cell Division; Cell Line, Tumor; DNA Fragmentation; DNA, Neoplasm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; K562 Cells; Kinetics; Lovastatin; Pravastatin; Pyrroles; Simvastatin | 2007 |
Hydrophobic but not hydrophilic statins enhance phagocytosis and decrease apoptosis of human peripheral blood cells in vitro.
Topics: Adult; Apoptosis; Atorvastatin; Dose-Response Relationship, Drug; Female; Flow Cytometry; Heptanoic Acids; Humans; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Leukocytes; Lovastatin; Male; Middle Aged; Phagocytes; Phagocytosis; Pravastatin; Pyrroles; Simvastatin | 2008 |
The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells.
Topics: Adult; Animals; Atorvastatin; Forkhead Transcription Factors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Mice; Mice, Inbred C57BL; Pravastatin; Pyrroles; T-Lymphocytes, Regulatory; Up-Regulation | 2008 |
Zooplankton chitobiase activity as an endpoint of pharmaceutical effect.
Topics: Acetylglucosaminidase; Animals; Atorvastatin; Biological Assay; Daphnia; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Environmental Monitoring; Fluoxetine; Heptanoic Acids; Lethal Dose 50; Lovastatin; Pyrroles; Sertraline; Water Pollutants, Chemical; Xenobiotics; Zooplankton | 2008 |
Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Databases, Factual; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Managed Care Programs; Odds Ratio; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion.
Topics: Atorvastatin; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Pravastatin; Pyrroles; Saphenous Vein; Simvastatin | 2007 |
Class effects of statins in elderly patients with congestive heart failure: a population-based analysis.
Topics: Aged; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Pravastatin; Pyrroles; Simvastatin; Survival Analysis; Treatment Outcome | 2008 |
Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Managed Care Programs; Middle Aged; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2008 |
Effect of APOE genotype on lipid levels in patients with coronary heart disease during a 3-week inpatient rehabilitation program.
Topics: Adult; Aged; Alleles; Apolipoprotein E2; Apolipoprotein E3; Apolipoprotein E4; Apolipoproteins E; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Decision Making; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genotype; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Inpatients; Linear Models; Lovastatin; Male; Middle Aged; Multivariate Analysis; Pravastatin; Predictive Value of Tests; Pyridines; Pyrroles; Simvastatin; Triglycerides | 2008 |
Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study.
Topics: Adult; Antipsychotic Agents; Atorvastatin; Cholesterol; Clozapine; Female; Fenofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Psychotic Disorders; Pyrroles; Retrospective Studies; Schizophrenia; Treatment Outcome; Triglycerides | 2008 |
Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Drugs, Generic; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Lipophilicity and cardiovascular outcome in patients with CHF.
Topics: Aged; Atorvastatin; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lovastatin; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Impact of adherence to statins on chronic heart failure in primary prevention.
Topics: Aged; Atorvastatin; Case-Control Studies; Databases, Factual; Female; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Lovastatin; Male; Middle Aged; Patient Compliance; Pravastatin; Primary Prevention; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2008 |
Statins induce apoptosis in ovarian cancer cells through activation of JNK and enhancement of Bim expression.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Atorvastatin; Bcl-2-Like Protein 11; cdc42 GTP-Binding Protein; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; JNK Mitogen-Activated Protein Kinases; Lovastatin; Membrane Proteins; Ovarian Neoplasms; Proto-Oncogene Proteins; Pyrroles; rac1 GTP-Binding Protein | 2009 |
The influence of statin medications on prostate-specific antigen levels.
Topics: Aged; Atorvastatin; Biomarkers, Tumor; Cholesterol, HDL; Cholesterol, LDL; Early Diagnosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Linear Models; Longitudinal Studies; Lovastatin; Male; Middle Aged; Multivariate Analysis; Pravastatin; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Risk Assessment; Simvastatin; Veterans | 2008 |
Modulation of human T cells signaling transduction by lovastatin.
Topics: Atorvastatin; Dose-Response Relationship, Drug; Down-Regulation; Electrophoretic Mobility Shift Assay; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; NF-kappa B; Pyrroles; Signal Transduction; T-Lymphocytes; Transcription Factor AP-1 | 2010 |
[Statin therapy and muscle disorders].
Topics: Atorvastatin; Biological Availability; Cytochrome P-450 Enzyme System; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Skeletal; Muscular Diseases; Pravastatin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis.
Topics: Alkylating Agents; Animals; Anticarcinogenic Agents; Anticholesteremic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Atorvastatin; Bexarotene; Cell Proliferation; Diet; Disease Models, Animal; Female; Genes, erbB-2; Heptanoic Acids; Lovastatin; Mammary Neoplasms, Experimental; Methylnitrosourea; Mice; Mice, Knockout; Mice, Transgenic; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Retinoid X Receptors; Tamoxifen; Tetrahydronaphthalenes; Treatment Outcome; Tumor Suppressor Protein p53 | 2009 |
Comparison of UV and charged aerosol detection approach in pharmaceutical analysis of statins.
Topics: Aerosols; Atorvastatin; Chromatography, High Pressure Liquid; Equipment and Supplies; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pyrroles; Simvastatin; Tablets | 2009 |
Statin-induced liver injury involves cross-talk between cholesterol and selenoprotein biosynthetic pathways.
Topics: Atorvastatin; Cell Line, Tumor; Cholesterol; Cytotoxins; Glutathione Peroxidase; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoenzymes; Lovastatin; Pyridines; Pyrroles; Reactive Oxygen Species; Selenoproteins; Signal Transduction; tert-Butylhydroperoxide; Thioredoxin-Disulfide Reductase | 2009 |
Regulation of steroid 5-alpha reductase type 2 (Srd5a2) by sterol regulatory element binding proteins and statin.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Animals; Atorvastatin; Azetidines; Cell Line, Tumor; Ezetimibe; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Liver; Lovastatin; Male; Mice; Promoter Regions, Genetic; Prostate; Prostatic Neoplasms; Pyrroles; Sterol Regulatory Element Binding Protein 2; Transfection | 2009 |
Autocrine amplification loop in statin-induced apoptosis of human melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; Atorvastatin; Autocrine Communication; Biological Factors; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Enzyme Activation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Melanoma; Pyridines; Pyrroles; Simvastatin; Time Factors | 2009 |
Serum levels of lipoprotein(a) and homocysteine in patients on hemodialysis who take hydroxymethylglutaryl-CoA reductase inhibitors, vitamin B6, and folic acid.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cross-Sectional Studies; Eating; Female; Folic Acid; Heptanoic Acids; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lipoprotein(a); Lovastatin; Male; Middle Aged; Pyrroles; Renal Dialysis; Risk Factors; Vitamin B 6; Vitamin B Complex; Young Adult | 2009 |
Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro.
Topics: Animals; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Mice; Myocytes, Cardiac; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Prenylation; Pyridines; Pyrroles; Rats; Sorafenib; Sunitinib | 2010 |
Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Atorvastatin; Azithromycin; Databases, Factual; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Rhabdomyolysis; Simvastatin | 2009 |
[Pharmaco-economic optimization of cholesterol-lowering treatment with statins].
Topics: Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Goals; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Spain; Sulfonamides | 2011 |
Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents.
Topics: Antineoplastic Agents; Apoptosis; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Proliferation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Ovarian Neoplasms; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Tumor Cells, Cultured | 2010 |
Statins and prostate cancer diagnosis and grade in a veterans population.
Topics: Aged; Aged, 80 and over; Anticarcinogenic Agents; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Biomarkers, Tumor; Cholesterol; Confounding Factors, Epidemiologic; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Lipids; Lovastatin; Male; Middle Aged; Multivariate Analysis; New England; Pravastatin; Proportional Hazards Models; Prostatic Neoplasms; Pyrroles; Risk Assessment; Severity of Illness Index; Simvastatin; Veterans | 2011 |
Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders.
Topics: Alzheimer Disease; Animals; Atorvastatin; Cholesterol; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Neurodegenerative Diseases; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides | 2011 |
[Retention behavior of statins in microemulsion liquid chromatography].
Topics: Atorvastatin; Chromatography, Liquid; Emulsions; Heptanoic Acids; Lovastatin; Models, Chemical; Pravastatin; Pyrroles; Simvastatin | 2011 |
Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
Topics: Atorvastatin; Benzylamines; beta-Cyclodextrins; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholesterol; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Female; Gefitinib; Heptanoic Acids; Humans; Lovastatin; Membrane Microdomains; Phosphorylation; Protein Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Thiophenes | 2011 |
Neurotoxic effect of statins on mouse neuroblastoma NB2a cell line.
Topics: Animals; Atorvastatin; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Neurites; Neuroblastoma; Pyrroles | 2011 |
Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Atorvastatin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cholesterol; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipid Metabolism; Liver Neoplasms; Lovastatin; Mice; Mice, Inbred C57BL; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tumor Suppressor Protein p53 | 2012 |
Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Survival; Dose-Response Relationship, Drug; Everolimus; Extracellular Signal-Regulated MAP Kinases; Imidazoles; Lovastatin; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; PC12 Cells; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinolines; Receptor, IGF Type 1; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2012 |
A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
Topics: Atorvastatin; Databases, Factual; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Skeletal; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tendons; United States; United States Food and Drug Administration | 2012 |
The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins.
Topics: Animals; Atorvastatin; Cell Communication; Disease Models, Animal; Endothelial Cells; Gene Expression; Hepatic Stellate Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Portal; Kruppel-Like Transcription Factors; Liver; Liver Circulation; Liver Cirrhosis, Experimental; Lovastatin; Male; Paracrine Communication; Pyrroles; Rats; Rats, Wistar; Simvastatin; Stress, Mechanical | 2013 |
CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control.
Topics: Aged; Atorvastatin; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Female; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pyrroles; Simvastatin | 2013 |
Mechanisms of the statins cytotoxicity in freshly isolated rat hepatocytes.
Topics: Animals; Atorvastatin; Cell Death; Cell Survival; Glutathione; Glutathione Disulfide; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Lovastatin; Male; Membrane Potential, Mitochondrial; Pyrroles; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Simvastatin | 2013 |
Comparison of effects of different statins on growth and steroidogenesis of rat ovarian theca-interstitial cells.
Topics: Animals; Atorvastatin; Cell Proliferation; Cells, Cultured; Female; Gonadal Steroid Hormones; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Metabolic Networks and Pathways; Ovary; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Theca Cells | 2014 |
[Renoprotective efficacy of different doses of statins in experimental acute renal failure].
Topics: Acute Kidney Injury; Administration, Topical; Animals; Atorvastatin; Creatine Kinase; Diuresis; Glomerular Filtration Rate; Glycerol; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Lovastatin; Pyrroles; Rats; Rhabdomyolysis; Simvastatin; Stomach; Urodynamics | 2014 |
Liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of simvastatin, lovastatin, atorvastatin, and their major metabolites in human plasma.
Topics: Adult; Aged; Atorvastatin; Calibration; Chromatography, Liquid; Heptanoic Acids; Humans; Lovastatin; Middle Aged; Pyrroles; Quality Control; Reproducibility of Results; Simvastatin; Tandem Mass Spectrometry | 2015 |
Lovastatin-Mediated Changes in Human Tendon Cells.
Topics: Atorvastatin; Cholesterol; Cytoskeleton; Gap Junctions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pyrroles; Simvastatin; Tendons | 2015 |